Looks Like MagicWorks Like Science
Social media advertising
Weakness of will
20 Cities And Growing!
We Apply a Holistic Approach
Some of the Services We Offer
We Always Work with They
Our executive team brings decades of experience in the Greek market and internationally, in launching products and meeting medical needs overcoming barriers to access.
LYSIS BIOTECH consists of executives highly experienced in the Greek legal requirements, market access hurdles, healthcare system particularities, mindset, and culture.
Sign Up for Our Newsletterto News and Great Events
LYSIS BIOTECH is the exclusive local representative to support Patient Access of Beleodaq®(belinostat) to eligible patients with relapsed and refractory PTCL in Greece
BELEODAQ® is a prescription medicine used to treat patients with a rare form of blood cancer called peripheral T-cell lymphoma (PTCL) that relapsed or does not respond to previous treatment. PTCL is a group of rare and aggressive non-Hodgkin lymphomas (NHL), a malignant lymphoproliferative disorder. PTCL accounts for approximately 10%-15% of all NHL cases.
BELEODAQ® (belinostat) is the only Histone Deacetylase Inhibitor (‘HDAC inhibitor’) globally to treat refractory/relapsed PTCL. The product received accelerated approval by the US Food and Drug Administration (‘FDA’) due to this rare disease’s high unmet medical need.
Our mission is bring specialty products with greater efficiency
Our mission is to bring specialty products to market faster and with greater efficiency, working in true partnership with quality providers.